[Vancomycin and teicoplanin: differential aspects].
Cobo
J
J
Unidad de Enfermedades Infecciosas, Hospital Ramón y Cajal, Madrid.
D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004352:Drug Resistance, Microbial; D004697:Endocarditis, Bacterial / Q000188:drug therapy; D004890:Erythema / Q000139:chemically induced / Q000453:epidemiology; D016908:Gram-Positive Bacterial Infections / Q000188:drug therapy*; D034381:Hearing Loss / Q000139:chemically induced / Q000453:epidemiology; D006801:Humans; D015994:Incidence; D007262:Infusions, Intravenous; D007674:Kidney Diseases / Q000139:chemically induced / Q000453:epidemiology; D011446:Prospective Studies; D017334:Teicoplanin / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D014640:Vancomycin / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D017334:Teicoplanin; D014640:Vancomycin